Approval Probability 71%
TA Base Rate26%
Adjusted LOA41%
ML RiskLOW_RISK
| NCT ID | Title | Phase | Status | Enrollment | Velocity | Design | Start | Completion | Last Updated | Sites | Countries |
|---|---|---|---|---|---|---|---|---|---|---|---|
| NCT00422487 | Safety and Tolerability Study of MBX-2044 in Patients With Type 2 Diabetes | PHASE2 | COMPLETED | 60 | — | — | Oct 1, 2006 | Sep 1, 2007 | May 1, 2015 | 1 | United States |
| Arm | Type | Description |
|---|---|---|
| MBX-2044 1.5 mg | EXPERIMENTAL | - |
| MBX-2044 4.5 mg | EXPERIMENTAL | - |
| MBX-2044 15 mg | EXPERIMENTAL | - |
| MBX-2044 30 mg | EXPERIMENTAL | - |
| MBX-2044 60 mg | EXPERIMENTAL | - |
| MBX-2044 90 mg | EXPERIMENTAL | - |
| Placebo | PLACEBO_COMPARATOR | - |
| Name | Type | Description |
|---|---|---|
| MBX-2044 | DRUG | MBX-2044 1.5 mg one capsule daily for 14 days |
| Placebo for MBX-2044 | DRUG | Placebo Intervention |
Inclusion Criteria: * Type 2 diabetes previously controlled with up to one or two non-TZD hypoglycemic agents including sulfonylureas (e.g., glyburide, glipizide, glimeprimide), meglitinides (e.g., Prandin®, Starlix®), metformin (e.g., Glucophage®), α-glucosidase inhibitors (e.g.,acarbose, miglitol...